Epigral Reports 6.84% Decline in Net Profit for March 2026 Quarter
Epigral consolidated net profit declines 6.84% in the March 2026 quarter
Business Standard
Image: Business Standard
Epigral's consolidated net profit fell by 6.84% to ₹80.95 crore in the March 2026 quarter, compared to ₹86.89 crore in the previous year. Despite a 17.29% increase in sales to ₹736.16 crore, the company's annual profit also declined by 7.19% to ₹331.97 crore.
- 01Net profit for the March 2026 quarter decreased by 6.84%.
- 02Sales increased by 17.29% compared to the previous year.
- 03Annual net profit fell by 7.19% for the year ending March 2026.
- 04Sales for the full year declined by 0.90%.
- 05Operating profit margin also saw a decrease.
Advertisement
In-Article Ad
Epigral's consolidated net profit for the quarter ending March 2026 decreased by 6.84%, amounting to ₹80.95 crore, down from ₹86.89 crore in the same quarter last year. This decline occurred despite a significant 17.29% increase in sales, which reached ₹736.16 crore compared to ₹627.63 crore in the previous year. For the entire fiscal year, the company's net profit dropped by 7.19% to ₹331.97 crore, down from ₹357.69 crore in the prior year. Sales for the full year also saw a slight decline of 0.90%, totaling ₹2527.18 crore compared to ₹2550.13 crore in the previous year. The operating profit margin decreased as well, indicating challenges in maintaining profitability despite higher sales.
Advertisement
In-Article Ad
The decline in net profit may affect investor confidence and could lead to tighter budgets within the company, potentially impacting employees and operational investments.
Advertisement
In-Article Ad
Reader Poll
Do you think Epigral will recover its profit margins in the next quarter?
Connecting to poll...
More about Epigral
Read the original article
Visit the source for the complete story.